Literature DB >> 26914454

The Clinical Significance of Uric Acid and Complement Activation in the Progression of IgA Nephropathy.

Yasar Caliskan1, Yasemin Ozluk, Dilara Celik, Nida Oztop, Aysun Aksoy, Ayse Serra Ucar, Halil Yazici, Isin Kilicaslan, Mehmet Sukru Sever.   

Abstract

BACKGROUND/AIMS: The aim of this study is to investigate the utility of clinical [age, gender, mean arterial pressure (MAP)] and laboratory parameters [eGFR, hemoglobin (Hgb), serum levels of creatinine, uric acid, albumin, proteinuria, hematuria] and also histopathological lesions (Oxford classification parameters, crescents, intensity and pattern of staining for C3, C1Q, IgA, IgG, IgM) as progression markers in patients with IgA Nephropathy (IgAN).
METHODS: A total of 111 IgAN patients with a follow-up period >1 year or who reached kidney failure [GFR category G5 chronic kidney disease (CKD)] <1 year were investigated. Primary endpoint was the development of kidney failure or eGFR decline ≥50% from the baseline. Kaplan-Meier and Cox proportional hazards analyses were performed.
RESULTS: Mean follow-up period was 33±29 months. Thirty-seven (33.3%) patients progressed to kidney failure and 4 (3.6%) patients developed eGFR decline ≥50% from the baseline after a median of 23 and 65 months, respectively. In multivariate Cox regression analysis, baseline levels of Hgb (HR:0.782, 95% CI 0.559-0.973, p=0.037), serum uric acid (HR:1.293, 95% CI 1.023-1.621, p=0.046), eGFR (HR:0.966, 95% CI 0.947-0.984, p=0.004) and intensity of C3 staining (HR:1.550, 95% CI 1.198-1.976, p=0.049) predicted primary endpoint. Serum uric acid level was associated independently with T score (β=0.303, p=0.005) in patients with eGFR>30 ml/min/m2.
CONCLUSIONS: Hyperuricemia and the deposition of C3 are independent risk factors for IgAN progression.
© 2016 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26914454     DOI: 10.1159/000443415

Source DB:  PubMed          Journal:  Kidney Blood Press Res        ISSN: 1420-4096            Impact factor:   2.687


  14 in total

1.  Predictive prognostic value of glomerular C3 deposition in IgA nephropathy.

Authors:  Minhua Xie; Yuze Zhu; Xutong Wang; Jingjing Ren; Haonan Guo; Bo Huang; Shulei Wang; Peiheng Wang; Yiming Liu; Yingchun Liu; Junjun Zhang
Journal:  J Nephrol       Date:  2022-07-04       Impact factor: 3.902

2.  Oxidative stress and macrophage infiltration in IgA nephropathy.

Authors:  Yasar Caliskan; Erol Demir; Ecem Karatay; Yasemin Ozluk; Safak Mirioglu; Ahmet Burak Dirim; Ayse Serra Artan; Sebahat Usta Akgul; Ozgur Akin Oto; Fatma Savran Oguz; Aydin Turkmen; Krista L Lentine; Halil Yazici
Journal:  J Nephrol       Date:  2021-11-16       Impact factor: 3.902

3.  How to take advantage of easily available biomarkers in patients with IgA nephropathy: IgA and C3 in serum and kidney biopsies.

Authors:  Małgorzata Mizerska-Wasiak
Journal:  Pediatr Nephrol       Date:  2022-08-02       Impact factor: 3.651

4.  Hyperuricemia and hypertriglyceridemia indicate tubular atrophy/interstitial fibrosis in patients with IgA nephropathy and membranous nephropathy.

Authors:  Bingman Liu; Liangyu Zhao; Qingqing Yang; Dongqing Zha; Xiaoyun Si
Journal:  Int Urol Nephrol       Date:  2021-04-24       Impact factor: 2.370

Review 5.  An evaluation of the roles of hematuria and uric acid in defining the prognosis of patients with IgA nephropathy.

Authors:  Ron Hogg
Journal:  Pediatr Nephrol       Date:  2021-05-13       Impact factor: 3.714

6.  The Serum Uric Acid Level Is Related to the More Severe Renal Histopathology of Female IgA Nephropathy Patients.

Authors:  Won Jung Choi; Yu A Hong; Ji Won Min; Eun Sil Koh; Hyung Duk Kim; Tae Hyun Ban; Young Soo Kim; Yong Kyun Kim; Seok Joon Shin; Seok Young Kim; Young Ok Kim; Chul Woo Yang; Yoon-Kyung Chang
Journal:  J Clin Med       Date:  2021-04-27       Impact factor: 4.241

7.  Add-On Effect of Angiotensin Receptor Blockade (Candesartan) on Clinical Remission in Active IgA Nephropathy Patients Treated with Steroid Pulse Therapy and Tonsillectomy: a Randomized, Parallel-Group Comparison Trial.

Authors:  Kentaro Kohagura; Hisatomi Arima; Hitoshi Miyasato; Tung-Huei Chang; Masanobu Yamazato; Hiroyuki Kobori; Akira Nishiyama; Kunitoshi Iseki; Yusuke Ohya
Journal:  Kidney Blood Press Res       Date:  2018-05-22       Impact factor: 2.687

8.  Clinicopathological features, risk factors, and outcomes of immunoglobulin A nephropathy associated with hepatitis B virus infection.

Authors:  Kailong Wang; Zhikai Yu; Yinghui Huang; Ke Yang; Ting He; Tangli Xiao; Yanlin Yu; Yan Li; Liang Liu; Jiachuan Xiong; Jinghong Zhao
Journal:  J Nephrol       Date:  2021-03-08       Impact factor: 3.902

9.  The influence of environmental factors on clinical pathological changes of patients with immunoglobulin A nephropathy from different areas of China.

Authors:  Ping Fan; Jianmin Song; Qun Chen; Xiaohong Cheng; Xusheng Liu; Chuan Zou; Bin Xie
Journal:  Ren Fail       Date:  2018-11       Impact factor: 2.606

10.  Relationship between serum C3/C4 ratio and prognosis of immunoglobulin A nephropathy based on propensity score matching.

Authors:  Yan Zhang; Shu-Wei Duan; Pu Chen; Zhong Yin; Yong Wang; Guang-Yan Cai; Xiang-Mei Chen
Journal:  Chin Med J (Engl)       Date:  2020-03-20       Impact factor: 2.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.